Stockscreener 앱 받기
2.21
11.24%
-0.28
시간 외 거래:
2.20
-0.010
-0.45%
전일 마감가:
$2.49
열려 있는:
$2.515
하루 거래량:
2.26M
Relative Volume:
0.92
시가총액:
$185.01M
수익:
$32.31M
순이익/손실:
$-237.09M
주가수익비율:
-0.7674
EPS:
-2.88
순현금흐름:
$-219.11M
1주 성능:
-9.43%
1개월 성능:
-22.73%
6개월 성능:
+76.80%
1년 성능:
-47.44%
1일 변동 폭
$2.20
$2.52
1주일 범위
$2.20
$2.665
52주 변동 폭
$0.9101
$4.22
Editas Medicine Inc Stock (EDIT) Company Profile
명칭
Editas Medicine Inc
전화
617-401-9000
주소
11 HURLEY ST., CAMBRIDGE, MA
EDIT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.21 | 211.79M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 개시 | H.C. Wainwright | Buy |
| 2024-12-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-13 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-11-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-05-09 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-10-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 개시 | Citigroup | Neutral |
| 2022-12-06 | 재개 | Credit Suisse | Neutral |
| 2022-11-18 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 개시 | BofA Securities | Neutral |
| 2021-10-19 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-09-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-08-09 | 업그레이드 | Truist | Hold → Buy |
| 2021-08-05 | 업그레이드 | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 개시 | Goldman | Sell |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-26 | 다운그레이드 | Truist | Buy → Hold |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 개시 | Robert W. Baird | Underperform |
| 2020-06-18 | 재개 | SunTrust | Buy |
| 2020-02-21 | 개시 | Wells Fargo | Equal Weight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-10 | 개시 | Guggenheim | Neutral |
| 2018-09-21 | 개시 | Raymond James | Outperform |
| 2018-05-15 | 재확인 | Chardan Capital Markets | Buy |
| 2018-02-13 | 개시 | CLSA | Underperform |
| 2018-01-23 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Hold |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-06-02 | 개시 | Jefferies | Hold |
| 2016-02-29 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-29 | 개시 | JP Morgan | Neutral |
| 2016-02-29 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Bought by XTX Topco Ltd - MarketBeat
Published on: 2025-08-09 06:19:25 - Newser
Quantitative breakdown of Editas Medicine Inc. recent moveInvestment Timeline and ROI Summary Report - Newser
Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) PT at $4.70 - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) EVP Linda Burkly Sells 5,121 Shares - MarketBeat
What makes Editas Medicine Inc. stock price move sharplyExit Strategy Guide With Risk Control Plan - Newser
Editas Medicine SVP Parison Amy Sells 679 Shares at $2.58/Share. - AInvest
Evaluating Editas Medicine Inc. with trendline analysisAI Stock Movement Forecast with Accuracy - Newser
How Interest Rate Changes Impact Editas Medicine Inc. Stock PerformanceAI Entry Timing Prediction for Swing Traders - Newser
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Bank of New York Mellon Corp - Defense World
Can you recover from losses in Editas Medicine Inc.Free Early Breakout Entry Point Notifications - Newser
Editas Medicine EVP Sells Shares to Meet Tax Obligations - TradingView
Trendlines Converge — Decision Point for Editas Medicine Inc.Real Profit Trade Plan Suggestions Shared Widely - beatles.ru
Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Why is Editas Medicine Inc. stock attracting strong analyst attentionAccess powerful market insights for free - Jammu Links News
How strong is Editas Medicine Inc. company’s balance sheetConsistently superior profits - Jammu Links News
What are analysts’ price targets for Editas Medicine Inc. in the next 12 monthsUnlock powerful trading alerts for success - Jammu Links News
When is Editas Medicine Inc. stock expected to show significant growthGet alerts on top growth stocks daily - Jammu Links News
What institutional investors are buying Editas Medicine Inc. stockBuild wealth faster with disciplined trading - Jammu Links News
Should I hold or sell Editas Medicine Inc. stock in 2025Maximize your portfolio’s earning power - Jammu Links News
Is Editas Medicine Inc. a growth stock or a value stockHigh-profit stock alerts - Jammu Links News
Cwm LLC Has $55,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
What is Editas Medicine Inc. company’s growth strategyTriple-digit profit margins - Jammu Links News
What are the technical indicators suggesting about Editas Medicine Inc.Invest smarter with actionable trading signals - Jammu Links News
Is Editas Medicine Inc. stock overvalued or undervaluedAchieve consistent double-digit growth rates - Jammu Links News
What catalysts could drive Editas Medicine Inc. stock higher in 2025High-yield trading alerts - Jammu Links News
Editas Medicine Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
What are the key drivers behind the recent increase in EDIT's trading volume? - AInvest
What is the dividend policy of Editas Medicine Inc. stockTop Growth Alerts With Proven Results - Jammu Links News
Editas Medicine Outperforms Medical Sector This Year Despite Zacks Rank #2 - AInvest
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? - Yahoo Finance
Editas MedicinePrimed For An Unlikely Comeback? It's Not Impossible - Seeking Alpha
EDIT SEC FilingsEditas Medicine Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Applying big data sentiment scoring on Editas Medicine Inc.Risk Controlled Picks With Real Returns Outlined - metal.it
Editas Medicine Inc. Flashes Buy Signal on Multi Timeframe ChartChart Driven High Reward Trading Setup Presented - metal.it
Published on: 2025-07-29 18:14:10 - metal.it
Published on: 2025-07-29 11:06:01 - metal.it
Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Gene Editing Market Exclusive Report with Detailed Study - openPR.com
Does Editas Medicine Inc. stock perform well during market downturnsHigh-velocity capital appreciation - Jammu Links News
Editas Medicine Inc (EDIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):